New Plaque Psoriasis Treatment


The recent breakthrough from Arcutis Biotherapeutics DERMIS-1 and DERMIS-2 studies of phosphodiesterase-4 (PDE4) inhibitor drug

in cream form for plaque psoriasis is considered important.


In these clinical trials, roflumilast creams were safe and well tolerated among plaque psoriasis patients so it can be included instead of corticosteroids in mild and moderate cases.

If approved after comparator trials roflumilast will be the second PDE4 inhibitor following Amgen’s Otezla (apremilast) is set to launch in markets by 2022 across the UK, US, France, Germany, Italy, Spain and Japan.

Source: Medindia


Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 


 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.

Leave a comment